Eikon operates proprietary single-molecule tracking instruments that industrialize super-resolution microscopy with high-throughput automation, allowing protein motion to be measured in millions of living cells per day. Its oblique line scan illumination technology, published in Nature Methods in 2025, improved the accuracy and sensitivity of single-protein measurements.
The platform's automated systems generate roughly a petabyte of imaging data per week, which machine learning algorithms analyze to support candidate selection. This engineering-driven approach to drug discovery distinguishes the company from conventional high-throughput screening operations.
Eikon competes in oncology drug development, where TLR7/8 agonists and PARP1-selective inhibitors address treatment approaches with large patient populations and established combination-therapy norms. Its registrational melanoma and non-small cell lung cancer trials target first-line settings currently dominated by checkpoint inhibitor combinations.
The company also applies its discovery platform to neurological disease, an area where imaging-based target identification remains uncommon. Its 2026 Nasdaq listing provides capital intended to advance the clinical pipeline through registrational readouts.
